Cargando…
Immunological Effects of Multikinase Inhibitors for Kidney Cancer: A Clue for Integration with Cellular Therapies?
The multikinase inhibitors Sunitinib and Sorafenib not only inhibit angiogenesis and tumor growth, but also have the potential of interacting with the function of the immune system. Presently available data seem to suggest that Sorafenib may exert immune suppressive effects, whilst the effects of Su...
Autores principales: | Porta, Camillo, Paglino, Chiara, Imarisio, Ilaria, Ganini, Carlo, Pedrazzoli, Paolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3119398/ https://www.ncbi.nlm.nih.gov/pubmed/21716852 |
Ejemplares similares
-
Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy
por: Porta, Camillo, et al.
Publicado: (2011) -
Modifying sunitinib schedule in advanced kidney cancer patients: Reflections from the results of the renal EFFECT trial
por: Porta, Camillo, et al.
Publicado: (2012) -
Cytokine-Based Immunotherapy for Advanced Kidney Cancer: Past Results and Future Perspectives in the Era of Molecularly Targeted Agents
por: Porta, Camillo, et al.
Publicado: (2007) -
Lingual metastasis from renal cell carcinoma: a case report and literature review
por: Ganini, Carlo, et al.
Publicado: (2012) -
Multikinase Inhibitor Treatment in Thyroid Cancer
por: Ancker, Ole Vincent, et al.
Publicado: (2019)